Canada Markets close in 4 hrs 16 mins

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3900+0.0200 (+0.46%)
As of 10:56AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close4.3700
Open4.4500
Bid4.2000 x 900
Ask4.4700 x 800
Day's Range4.3900 - 4.4500
52 Week Range1.7000 - 8.8000
Volume1,047
Avg. Volume55,857
Market Cap81.705M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.7670
Earnings DateAug. 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
    Business Wire

    DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform.

  • DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study
    Business Wire

    DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dosing of the first participants in the diabetic kidney disease (DKD) cohort of the REDUX Phase II Chronic Kidney Disease (CKD) study. In total, 16 additional participants have been enrolled in the REDUX study in the past six weeks, 11 of which were enrolled in the DKD cohort III, bringing the total enrolled participants to 34, including 11 African American subjects into cohort I and 12 subjects with IgA Nephropathy (IgAN) into cohort II of the REDUX study.

  • DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results
    Business Wire

    DiaMedica Provides a Business Update and Second Quarter 2020 Financial Results

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and six months ended June 30, 2020. DiaMedica will host a conference call tomorrow, August 12, 2020, at 7:00 a.m. Central Time to discuss its business update and second quarter financial results.